Discover CME, tools, and guideline-focused education to improve your knowledge - and patient outcomes.
Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy
Kevin Kalinsky MD, MS
Komal Jhaveri, MD, FACP
Advancing Myasthenia Gravis (MG) Treatment Through Guideline Updates and Emerging Therapies
October 30, 2025
San Francisco, California
Non-CF Bronchiectasis: How Radiologists Can Drive Better Outcomes
Robert D. Suh, MD
Lea Azour, MD
Ashwin Basavaraj, MD
Expert Perspectives From AUA 2025: Contextualizing the Evolving Landscape of Bladder Cancer
Neal Shore, MD, FACS
Sarah Psutka, MD, MS
New Strategies for Individualizing Treatment in DME
Luis A. Gonzalez, MD, MPH
Jeremiah Brown Jr., MD, MS, FASRS
From Doctor-Speak to Patient-Speak: Bridging the Communication Gap
First Results From Cohort 4 of the SunRISe-1 Trial
SunRISe-1: 1-Year Durability and Patient-Reported Outcomes Results
HER2 in Bladder Cancer: Breaking Through the Molecular Frontier
Vadim S. Koshkin, MD
Chairperson's Perspective: Innovative Approaches to IBS-C: Personalized Treatment for Better Outcomes
Darren Brenner, MD
What’s New In Glaucoma?
Paul Petrakos, DO, MS
Justin Schweitzer, OD, FAAO
I. Paul Singh, MD
Sarah H. Van Tassel, MD
Managing Side Effects in FcRn Therapy: Best Practices for gMG
Vera Bril, MD
Nicholas J. Silvestri, MD
New Frontiers in MG: How FcRn Antagonists Are Changing MG Therapy
Treatment Advances in Generalized Myasthenia Gravis: Addressing the Nuances of its Underlying Immunopathology
Hans Katzberg, MD
Trial in Progress: Phase 3 MoonRISe-3 Study
Treatment Advances in Generalized Myasthenia Gravis: A Pathophysiology-Driven Framework Leveraging FcRn Therapeutics
Neelam Goyal, MD
A Scientific Look at FcRn Antagonists: Mechanisms of Action Explained
Preventing Myasthenic Crisis: Early Signs and Critical Interventions
Treatment Advances in Generalized Myasthenia Gravis: Clinical and Laboratory Criteria for Diagnosis and Optimal Treatment Selection
Jonathan Strober, MD
Traditional MG Treatments: Balancing Benefits, Risks, and Side Effect Management
Ocular to Generalized MG: How and Why the Disease Evolves
Autoantibodies Explained: Anti-AChR, Anti-MuSK, and Their Diagnostic Role
Precision Medicine for gMG: Tailoring Treatments Based on Patient Profiles
Chairperson’s Perspective: Treating At-Risk MASH: What Are You Waiting For?
Mazen Noureddin, MD, MHSc
What’s New in Glaucoma Therapy?
What’s New in Subconjunctival MIBS
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.